פיפרצילין/ טזובקטם פאנפרמה 2 גרם/ 250 מ"ג
pharmalogic ltd - piperacillin as sodium 2 g; tazobactam as sodium 250 mg - powder for solution for infusion - tazobactam - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. pipoeracillin/tazobactam in combination with an aminoglycoside is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appencicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
טאזוצין 2.25 גרם
neopharm ltd - piperacillin as sodium 2 g/vial; tazobactam sodium 0.25 g/vial - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazocin in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
טאזוצין 4.5 גרם
neopharm ltd - piperacillin as sodium 4 g; tazobactam as sodium 0.5 g - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazocin in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
טאזוצין 4.5 גרם
neopharm ltd - piperacillin as sodium 4 g; tazobactam sodium 0.5 g - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazocin in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
טאזופיפ 2.25 ג'
perrigo israel agencies ltd - piperacillin as sodium 2000 mg; tazobactam as sodium 250 mg - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazo-pip in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
טאזופיפ 2.25 ג'
perrigo israel agencies ltd - piperacillin as sodium 2000 mg; tazobactam as sodium 250 mg - powder for solution for injection - piperacillin and enzyme inhibitor - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. tazo-pip in combination with an aminoglycoside, is indicated for suspected bacterial infections in neutropenic adults or children. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
פלוטיפורם 505
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.
פלוטיפורם 1255
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.